首页> 外文期刊>Oncology Research >Radiosensitization of Non-Small Cell Lung Cancer Cells by Inhibition of TGF-beta 1 Signaling With SB431542 Is Dependent on p53 Status
【24h】

Radiosensitization of Non-Small Cell Lung Cancer Cells by Inhibition of TGF-beta 1 Signaling With SB431542 Is Dependent on p53 Status

机译:通过抑制TGF-beta 1信号与SB431542的非小细胞肺癌细胞的放射增敏依赖于p53状态

获取原文
获取原文并翻译 | 示例
       

摘要

Although medically inoperable patients with stage I non-small cell lung cancer cells (NSCLC) are often treated with stereotactic body radiation therapy, its efficacy can be compromised due to poor radiosensitivity of cancer cells. Inhibition of transforming growth factor-beta 1 (TGF-beta 1) using LY364947 and LY2109761 has been demonstrated to radiosensitize cancer cells such as breast cancer, glioblastoma, and lung cancer. Our previous results have demonstrated that another potent and selective inhibitor of TGF-beta 1 receptor kinases, SB431542, could radiosensitize H460 cells both in vitro and in vivo. In the present study, we investigated whether SB431542 could radiosensitize other NSCLC cell lines, trying to explore the potential implication of this TGF-beta 1 inhibitor in radiotherapy for NSCLC patients. The results showed that A549 cells were significantly radiosensitized by SB431542, whereas no radiosensitizing effect was observed in H1299 cells. Interestingly, both H460 and A549 cells have wild-type p53, while H1299 cells have deficient p53. To study whether the radiosensitizing effect of SB431542 was associated with p53 status of cancer cells, the p53 of H460 cells was silenced using shRNA transfection. Then it was found that the radiosensitizing effect of SB431542 on H460 cells was not observed in H460 cells with silenced p53. Moreover, X-irradiation caused rapid Smad2 activation in H460 and A549 cells but not in H1299 and H460 cells with silenced p53. The Smad2 activation postirradiation could be abolished by SB431542. This may explain the lack of radiosensitizing effect of SB431542 in H1299 and H460 cells with silenced p53. Thus, we concluded that the radiosensitizing effect of inhibition of TGF-beta 1 signaling in NSCLC cells by SB431542 was p53 dependent, suggesting that using TGF-beta 1 inhibitor in radiotherapy may be more complicated than previously thought and may need further investigation.
机译:尽管医学上无法手术的I期非小细胞肺癌细胞(NSCLC)患者经常接受立体定向放射疗法治疗,但由于癌细胞的放射敏感性差,其疗效可能会受到损害。已经证明,使用LY364947和LY2109761抑制转化生长因子β1(TGF-beta 1)可以使乳腺癌,胶质母细胞瘤和肺癌等癌细胞发生放射增敏作用。我们以前的结果表明,另一种有效且选择性的TGF-β1受体激酶抑制剂SB431542可在体外和体内对H460细胞进行放射增敏。在本研究中,我们调查了SB431542是否可以对其他NSCLC细胞放射增敏,试图探索这种TGF-β1抑制剂在NSCLC患者放射治疗中的潜在意义。结果表明,SB431542对A549细胞具有明显的放射增敏作用,而在H1299细胞中未观察到放射增敏作用。有趣的是,H460和A549细胞均具有野生型p53,而H1299细胞均具有缺陷的p53。为了研究SB431542的放射增敏作用是否与癌细胞的p53状态有关,使用shRNA转染沉默了H460细胞的p53。然后发现在沉默p53的H460细胞中未观察到SB431542对H460细胞的放射增敏作用。此外,X射线照射在H460和A549细胞中引起了Smad2的快速激活,但在沉默了p53的H1299和H460细胞中却没有引起。 Smad2激活后辐照可以被SB431542取消。这可以解释SB431542在p53沉默的H1299和H460细胞中缺乏放射增敏作用。因此,我们得出结论,SB431542抑制NSCLC细胞中TGF-β1信号的放射增敏作用是p53依赖性的,这表明在放射治疗中使用TGF-β1抑制剂可能比以前认为的要复杂,可能需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号